Q1 2026 Metropolis Healthcare Ltd Earnings Call Transcript
Key Points
- Metropolis Healthcare Ltd (BOM:542650) reported a 23% growth in revenues for Q1 FY26, driven by strong organic growth and strategic acquisitions.
- The company achieved a 13.2% organic growth in revenues, supported by increased volumes and improved realizations.
- Metropolis is expanding its presence in Tier 2 and Tier 3 towns, enhancing its B2C footprint and brand presence.
- The integration of recent acquisitions is progressing smoothly, with synergies already being realized in lab consolidation and procurement efficiencies.
- The company is focusing on innovation and scientific depth, establishing a center of excellence in oncology diagnostics to differentiate itself in the market.
- The integration of Core Diagnostics is currently dragging down the consolidated EBITDA margin due to its low single-digit margin profile.
- PAT for Q1 was negative, primarily due to high depreciation and interest costs associated with Core Diagnostics.
- The competitive landscape remains challenging, with health tech players raising prices and transitioning to a value-based growth approach.
- The company is gradually withdrawing from low-margin government contracts, which may impact revenue from this segment.
- There is uncertainty regarding the impact of GLP-1 medications on healthcare delivery, as these drugs are relatively new and their long-term effects are not fully understood.
Ladies and gentlemen. Good day, and welcome to the Q1 FY26 earnings conference call of Metropolis Healthcare Limited, hosted by JM Financial. This conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions, and expectation of the company as on date of this call.
These statements do not guarantee the future performance of the company and it may involve risk and uncertainties that are difficult to predict. (Operator Instructions) Please note that this conference is being recorded.
With this, I now hand the conference over to Mr. Amey Chalke from JM Financial. Thank you and over to you, sir.
Yes. Thank you, Shruti. Good morning, everyone. I am at Amey Chalke on behalf of JM Financial. Welcome you all to the 1Q FY26 earnings conference call of Metropolis Healthcare. From Metropolis, we have with us today, Ms. Ameera Shah, Chairman and Whole-Time Director; Mr. Surendran, Managing Director and Chief Executive Officer; Mr.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
